ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0655

A Novel Association Between Lipodermatosclerosis and Key Vascular Outcomes in Systemic Sclerosis

Srijana Davuluri1, Puneet Kapoor2, Swarna Nandyala2, David Fiorentino3, Julia Simard4 and Lorinda Chung5, 1Stanford University- School of Medicine, Sunnyvale, CA, 2Stanford University- School of Medicine, Palo Alto, CA, 3Department of Dermatology, Stanford University, Redwood City, CA, 4Department of Epidemiology & Population Health, Stanford University School of Medicine, Stanford, CA, 5Department of Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, Woodside, CA

Meeting: ACR Convergence 2023

Keywords: Cohort Study, Dermatology, Scleroderma, skin, Systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: (0609–0672) Systemic Sclerosis & Related Disorders – Clinical Poster I: Research

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Lipodermatosclerosis (LDS) is a progressive manifestation of chronic venous insufficiency characterized by distinctive lower extremity changes, including an “inverted champagne bottle” appearance, skin hyperpigmentation, and occasionally, non-healing ulcers. (see Figure 1) While LDS is not extensively studied in the context of connective tissue diseases, it shares similar pathogenic pathways with systemic sclerosis (SSc), where vasculopathy leads to tissue hypoxia, inflammation, and subsequent fibrosis of the skin and subcutaneous tissues. This study estimated the prevalence of LDS in SSc, examined the demographic and SSc-related characteristics of patients with LDS, and estimated the association between LDS and major vascular outcomes in patients with SSc.

Methods: We performed a retrospective cohort analysis of adult patients who had prospectively enrolled in our Autoimmune Skin Disease Registry between 2004-2023 and met ACR/EULAR 2013 classification criteria for SSc. Descriptive statistics were used to summarize data, and chi-square/Fisher’s exact test and t-test/Mann-Whitney U test were employed to compare categorical and continuous variables, respectively. Logistic regression estimated prevalence odds ratios (pOR) and 95% confidence intervals of the association between LDS and a composite macrovascular outcome measure, including digital gangrene and/or renal crisis and/or pulmonary hypertension, adjusted for age and follow-up time. A. sensitivity analysis was conducted for the outcome of pulmonary hypertension (PH).

Results: Among 586 SSc patients, 4% (N=25) had LDS. Baseline demographic and disease features were similar between patients with and without LDS (Tables 1 and 2) with the exception that patients with LDS had higher frequencies of cardiac arrhythmias, heart failure, and PH. Among patients with LDS, 36% were either discharged to hospice or died during a median follow-up time of 7.5 (IQR- 3.9, 11.4) years, compared to 20.5% of patients without LDS followed for 5.6 (IQR-1.5, 9.8) years. LDS was associated with the composite vascular outcome in adjusted analysis with pOR=2.36 [1.02-5.45], but this was primarily driven by the association with PH. Sensitivity analysis confirmed an elevated pOR between LDS and pulmonary hypertension, with an adjusted pOR of 3.20 [1.37-7.49].

Conclusion: LDS was diagnosed in 4% of SSc patients evaluated at a multi-disciplinary Rheumatologic Dermatology Clinic. Patients with LDS have more than two-fold higher prevalence of a composite macrovascular outcome and more than three-fold higher prevalence of pulmonary hypertension. We conclude that LDS could portend severe vasculopathic manifestations in SSc, however, temporality could not be determined by our analyses. Clinicians should recognize the clinical features of LDS in SSc patients and closely monitor these patients for PH and other macrovascular complications.

Supporting image 1

Figure 1 A 66-year-old female with SSc having lipodermatosclerosis of bilateral lower extremities

Supporting image 2

Table 1- Comparison of demographic and SSc disease features between patients with and without LDS

Supporting image 3

Table 2- Comparison of the scleroderma complications among those with and without LDS.


Disclosures: S. Davuluri: None; P. Kapoor: None; S. Nandyala: None; D. Fiorentino: Acelyrin, 2, Amgen, 2, Argenyx, 2, 12, Contracted research, Biogen, 2, Bristol-Myers Squibb(BMS), 2, EMD Serono, 12, Contracted research, Gilead, 2, Janssen, 2, Merck, 2, Pfizer, 2, 12, Contracted research, UCB, 2; J. Simard: None; L. Chung: Eicos Science, 1, 2, Eli Lilly, 1, 2, Genentech, 1, 2, IgM biosciences, 1, 2, Janssen, 1, 2, Kyverna, 1, 2, Mitsubishi Tanabe, 1, 2.

To cite this abstract in AMA style:

Davuluri S, Kapoor P, Nandyala S, Fiorentino D, Simard J, Chung L. A Novel Association Between Lipodermatosclerosis and Key Vascular Outcomes in Systemic Sclerosis [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/a-novel-association-between-lipodermatosclerosis-and-key-vascular-outcomes-in-systemic-sclerosis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-novel-association-between-lipodermatosclerosis-and-key-vascular-outcomes-in-systemic-sclerosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology